The AR-V7 target genes mentioned in this review are linked with a more aggressive phenotype of PCa (Figure 4), aligning with clinical evidence concerning prognosis and diagnosis; whereby if a patient’s cancer expresses these truncated AR-Vs, the patient is more likely to have a more aggressive form of PCa, compared to patients with tumours only expressing AR-FL (26, 256). This evidence concerns the gene AR and posterior cortical atrophy.